News Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 09:00:41 31/05/2024 pm IST			5-day change	1st Jan Change
93.17 ^CHF	+2.13%		+1.56%	+9.78%

02/06	Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	RE
31/05	NOVARTIS AG : UBS reiterates its Buy rating	ZD

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06	RE
NOVARTIS AG : UBS reiterates its Buy rating	31/05	ZD
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	31/05	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	31/05	MT
NOVARTIS AG : Jefferies remains its Buy rating	31/05	ZD
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	31/05	MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	31/05	MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	31/05	MT
Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease	31/05	PU
Novartis: positive trial results in chronic myeloid leukemia	31/05	CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	31/05	MT
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML	31/05	GL
Novartis: efficacy of remibrutinib in urticaria -USC	31/05	CF
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	31/05	MT
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	31/05	GL
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	31/05	DJ
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target	30/05	MT
Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	30/05	MT
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs	30/05	ZD
Novartis: positive phase III results in C3G	27/05	CF